Patient characteristics
| Post-inpatient (n=445) | Community (n=455) | |
| Female | 202/444 (45.5%) | 275/455 (60.4%) |
| Mean age (SD) | 61.0 (17.38) | 48.9 (14.01) |
| BAME | 114/438 (26.0%) | 153/448 (34.1%) |
| Smoking | ||
| No | 35/190 (18.4%) | 51/163 (31.3%) |
| Yes | 10/190 (5.3%) | 8/163 (4.9%) |
| Ex-smoker | 145/190 (76.3%) | 104/163 (63.8%) |
| Residence prior to admission | ||
| Home | 392/428 (91.6%) | 414/427 (96.7%) |
| Residential home | 3/428 (0.7%) | 0/427 (0.0%) |
| Nursing home | 30/428 (7.0%) | 6/427 (1.4%) |
| Mental unit | 2/428 (0.5%) | 4/427 (0.9%) |
| Sheltered accommodation | 1/428 (0.2%) | 2/427 (0.5%) |
| Other | 0/428 (0.0%) | 1/427 (0.2%) |
| Comorbid conditions | ||
| Diabetes | 110/424 (25.9%) | 52/423 (12.3%) |
| Frail | 89/430 (20.7%) | 9/426 (2.1%) |
| Mental health | 133/429 (31.0%) | 142/424 (33.5%) |
| CKD | 49/426 (11.5%) | 11/424 (2.6%) |
| CTD | 74/426 (17.4%) | 52/424 (12.3%) |
| CVD | 44/425 (10.4%) | 13/424 (3.1%) |
| Cancer | 47/428 (11.0%) | 27/424 (6.4%) |
| Asthma | 94/431 (21.8%) | 124/427 (29.0%) |
| COPD | 52/429 (12.1%) | 18/425 (4.2%) |
| Other respiratory | 30/430 (7.0%) | 17/425 (4.0%) |
| Number of comorbid conditions | ||
| None | 100/445 (22.5%) | 159/455 (35.0%) |
| 1 | 109 (24.5%) | 125 (27.5%) |
| 2 | 87 (19.6%) | 97 (21.3%) |
| 3 | 58 (13.0%) | 57 (12.5%) |
| 4 | 48 (10.8%) | 9 (2.0%) |
| 5+ | 43 (9.7%) | 8 (1.8%) |
| Medications | ||
| ACEi | 72/425 (16.9%) | 47/411 (11.4%) |
| AR2b | 44/424 (10.4%) | 24/410 (5.9%) |
| Sildenafil | 12/424 (2.8%) | 4/410 (1.0%) |
| NSAID | 60/425 (14.1%) | 43/410 (10.5%) |
| Immunosuppressants | 22/425 (5.2%) | 16/410 (3.9%) |
| LABA | 67/424 (15.8%) | 39/410 (9.5%) |
| ICS | 85/424 (20.1%) | 68/410 (16.6%) |
| LAMA | 30/424 (7.1%) | 10/410 (2.4%) |
| DOAC or other anticoagulant | 77/424 (18.2%) | 22/411 (5.4%) |
| HQ | 5/424 (1.2%) | 2/410 (0.5%) |
| Oral diabetes medication | 71/424 (16.8%) | 33/410 (8.1%) |
| Insulin | 20/424 (4.7%) | 9/410 (2.2%) |
| Azithromycin | 3/424 (0.7%) | 0/410 (0.0%) |
| Beta-blockers | 78/425 (18.4%) | 36/410 (8.8%) |
| PPI | 154/425 (36.2%) | 88/410 (21.5%) |
| Antidepressants | 76/424 (17.9%) | 79/410 (19.3%) |
ACEi, ACE inhibitor; AR2b, angiotensin II receptor blocker; BAME, Black, Asian, Minority Ethnic; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CTD, connective tissue disorder; CVD, cardiovascular disease; DOAC, direct oral anticoagulant; HQ, hydroxychloroquine; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor.